Cancer Research and Treatment

Volume 46(4); October 2014

Original Articles

Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Bhumsuk Keam, Dong-Wan Kim, Jin Hyun Park, Jeong-Ok Lee, Tae Min Kim, Se-Hoon Lee, Doo Hyun Chung, Dae Seog Heo; Cancer Res Treat. 2014;46(4):323-330. Published online July 14, 2014; DOI: https://doi.org/10.4143/crt.2013.120

Purpose
The aim of this study was to develop a pragmatic nomogram for prediction of progressionfree survival (PFS) for the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in EGFR mutant non-small cell lung cancer (NSCLC).
Materials and Methods
A total of 306 recurred or metastatic NSCLC patients with EGFR mutation, who received EGFR TKIs, were enrolled in this study. We developed the nomogram, using a Cox proportional hazard regression model for PFS.
Results
The median PFS was 11.2 months. Response rate to EGFR TKI was 71.9%. Multivariate Cox model identified disease status, performance status, chemotherapy line, response to EGFR TKI, and bone metastasis as independent prognostic factors, and the nomogram for PFS was developed, based on these covariates. The concordance index for a nomogram was 0.708, and the calibration was also good.
Conclusion
We developed a nomogram, based on clinical characteristics, for prediction of the PFS to EGFR TKI in NSCLC patients with EGFR mutation.

Citations

Citations to this article as recorded by

To establish a prognostic model of epidermal growth factor receptor mutated non-small cell lung cancer patients based on Least Absolute Shrinkage and Selection Operator regression
Bowen Li, Xiaopeng Zhang
European Journal of Cancer Prevention.2024; 33(4): 368. CrossRef
A predictive model of computed tomography and clinical features of EGFR gene mutation in lung adenocarcinoma
Youjian Yao, Nengde Zhang, Caiwei Lu, Lianhua Liu, Yu Fu, Mei Gui
Science Progress.2024;[Epub] CrossRef
Hallmark guided identification and characterization of a novel immune-relevant signature for prognostication of recurrence in stage I–III lung adenocarcinoma
Yongqiang Zhang, Zhao Yang, Yuqin Tang, Chengbin Guo, Danni Lin, Linling Cheng, Xun Hu, Kang Zhang, Gen Li
Genes & Diseases.2023; 10(4): 1657. CrossRef
Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI
John Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, Ching-Fu Chang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, Chiao-En Wu
Cancers.2022; 14(4): 977. CrossRef
Establishment of prognostic nomograms for predicting the progression free survival of EGFR‐sensitizing mutation, advanced lung cancer patients treated with EGFR‐TKIs
Xinyang Du, Hua Bai, Zhijie Wang, Jianchun Daun, Zheng Liu, Jiachen Xu, Geyun Chang, Yixiang Zhu, Jie Wang
Thoracic Cancer.2022; 13(9): 1289. CrossRef
Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data
Lourdes Gutiérrez, Ana Royuela, Enric Carcereny, Rafael López-Castro, Delvys Rodríguez-Abreu, Bartomeu Massuti, José Luis González-Larriba, Rosario García-Campelo, Joaquim Bosch-Barrera, María Guirado, Carlos Camps, Manuel Dómine, Reyes Bernabé, Joaquín C
BMC Cancer.2021;[Epub] CrossRef
The Ki-67 Proliferation Index-Related Nomogram to Predict the Response of First-Line Tyrosine Kinase Inhibitors or Chemotherapy in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor-Mutant Status
Weiguo Gu, Mingbin Hu, Linlin Xu, Yuanhui Ren, Jinhong Mei, Weijia Wang, Chunliang Wang
Frontiers in Medicine.2021;[Epub] CrossRef
A nomogram to predict outcomes of lung cancer patients after pneumonectomy based on 47 indicators
Bo Cheng, Cong Wang, Bing Zou, Di Huang, Jinming Yu, Yufeng Cheng, Xue Meng
Cancer Medicine.2020; 9(4): 1430. CrossRef
Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer
Chan-Young Ock, Shin-Hye Yoo, Bhumsuk Keam, Miso Kim, Tae Min Kim, Yoon Kyung Jeon, Dong-Wan Kim, Doo Hyun Chung, Dae Seog Heo
The Korean Journal of Internal Medicine.2019; 34(5): 1116. CrossRef
The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy
Ji Young Choi, Miso Kim, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo, Seong Jin Jo
Cancer Research and Treatment.2019; 51(1): 169. CrossRef
Development and validation of nomograms for predicting survival probability of patients with advanced adenocarcinoma in different EGFR mutation status
Hsi-Chieh Chen, Elise Chia-Hui Tan, Chih-Hsien Liao, Zhong-Zhe Lin, Ming-Chin Yang, Wan-Teck Lim
PLOS ONE.2019; 14(8): e0220730. CrossRef
An inflammation-related nomogram for predicting the survival of patients with non-small cell lung cancer after pulmonary lobectomy
Ying Wang, Xiao Qu, Ngar-Woon Kam, Kai Wang, Hongchang Shen, Qi Liu, Jiajun Du
BMC Cancer.2018;[Epub] CrossRef
Clinical nomograms: Is a picture worth a thousand words?
Kaitlin C. McLoughlin, R. Taylor Ripley
The Journal of Thoracic and Cardiovascular Surgery.2017; 153(2): 470. CrossRef
Prognostic Factors and Scoring Model for Survival in Metastatic Biliary Tract Cancer
Hyung Soon Park, Ji Soo Park, You Jin Chun, Yun Ho Roh, Jieun Moon, Hong Jae Chon, Hye Jin Choi, Joon Seong Park, Dong Ki Lee, Se-Joon Lee, Dong Sup Yoon, Hei-Cheul Jeung
Cancer Research and Treatment.2017; 49(4): 1127. CrossRef
An international epidemiological analysis of young patients with non-small cell lung cancer (AduJov-CLICaP)
Luis Corrales-Rodríguez, Oscar Arrieta, Luis Mas, Renata Báez-Saldaña, Omar Castillo-Fernández, Normand Blais, Claudio Martín, Melissa Juárez, Priyanka Khanna, Allan Ramos-Esquivel, Ludwing Bacon, Leonardo Rojas, Beatriz Wills, George Oblitas, María Angel
Lung Cancer.2017; 113: 30. CrossRef
The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors
Hyungjin Kim, Chang Min Park, Bhumsuk Keam, Sang Joon Park, Miso Kim, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo, Jin Mo Goo, Fan Yang
PLOS ONE.2017; 12(11): e0187500. CrossRef
Nomograms for predicting progression and efficacy of post-operation radiotherapy in IIIA-pN2 non-small cell lung cancer patients
Baozhong Zhang, Zhiyong Yuan, Lujun Zhao, Qingsong Pang, Ping Wang
Oncotarget.2017; 8(23): 37208. CrossRef
A Nomogram to Predict Recurrence and Survival of High-Risk Patients Undergoing Sublobar Resection for Lung Cancer: An Analysis of a Multicenter Prospective Study (ACOSOG Z4032)
Michael S. Kent, Sumithra J. Mandrekar, Rodney Landreneau, Francis Nichols, Nathan R. Foster, Thomas A. DiPetrillo, Bryan Meyers, Dwight E. Heron, David R. Jones, Angelina D. Tan, Sandra Starnes, Joe B. Putnam, Hiran C. Fernando
The Annals of Thoracic Surgery.2016; 102(1): 239. CrossRef
Advanced non-Small cell lung cancer patients at the extremes of age in the era of epidermal growth factor receptor tyrosine kinase inhibitors
Yu-Mu Chen, Chien-Hao Lai, Kun-Ming Rau, Cheng-Hua Huang, Huang-Chih Chang, Tung-Ying Chao, Chia-Cheng Tseng, Wen-Feng Fang, Yung-Che Chen, Yu-Hsiu Chung, Yi-Hsi Wang, Mao-Chang Su, Kuo-Tung Huang, Shih-Feng Liu, Hung-Chen Chen, Ya-Chun Chang, Yu-Ping Cha
Lung Cancer.2016; 98: 99. CrossRef
Prognostic Scoring Index for Patients with Metastatic Pancreatic Adenocarcinoma
Hyung Soon Park, Hye Sun Lee, Ji Soo Park, Joon Seong Park, Dong Ki Lee, Se-Joon Lee, Dong Sup Yoon, Min Goo Lee, Hei-Cheul Jeung
Cancer Research and Treatment.2016; 48(4): 1253. CrossRef

21,250 View
129 Download
24 Web of Science
20 Crossref

Clinical Usefulness of Hydromorphone-OROS in Improving Sleep Disturbances in Korean Cancer Patients: A Multicenter, Prospective, Open-Label Study: Seong Hoon Shin, Ho Sup Lee, Yang Soo Kim, Young Jin Choi, Sung Hyun Kim, Hyuk Chan Kwon, Sung Yong Oh, Jung Hun Kang, Chang Hak Sohn, Sang Min Lee, Jin Ho Baek, Young Joo Min, Choongrak Kim, Joo Seop Chung; Cancer Res Treat. 2014;46(4):331-338. Published online July 21, 2014; DOI: https://doi.org/10.4143/crt.2013.130

Abstract PDF PubReader ePub

Purpose
To evaluate the efficacy of hydromorphone-OROS (HM-OROS) in reducing sleep disturbance and relieving cancer pain. Materials and Methods One hundred twenty cancer patients with pain (numeric rating scale [NRS] ≥ 4) and sleep disturbance (NRS ≥ 4) were evaluated. The initial HM-OROS dosing was based on previous opioid dose (HM-OROS:oral morphine=1:5). Dose adjustment of the study drug was permitted at the investigator’s discretion. Pain intensity, number of breakthrough pain episodes, and quality of sleep were evaluated. Results A total of 120 patients received at least one dose of HM-OROS; 74 of them completed the final assessment. Compared to the previous opioids, HM-OROS reduced the average pain NRS from 5.3 to 4.1 (p < 0.01), worst pain NRS from 6.7 to 5.4 (p < 0.01), sleep disturbance NRS from 5.9 to 4.1 (p < 0.01), incidence of breakthrough pain at night from 2.63 to 1.53 times (p < 0.001), and immediate-release opioids use for the management of breakthrough pain from 0.83 to 0.39 times per night (p = 0.001). Of the 74 patients who completed the treatment, 83.7% indicated that they preferred HM-OROS to the previous medication. The adverse events (AEs) were somnolence, asthenia, constipation, dizziness, and nausea. Conclusion HM-OROS was efficacious in reducing cancer pain and associated sleep disturbances. The AEs were manageable.

Citations

Citations to this article as recorded by

Pain and Analgesic Related Insomnia
Jana Mlíchová, Zoltán Paluch, Ondřej Šimandl
Pain Management Nursing.2023; 24(3): 254. CrossRef
Initial titration with 200 μg fentanyl buccal tablets: a retrospective safety analysis in Korean cancer patients
Mi-Young Kwon, Ha-Na Cho, Dong-Hoe Koo, Yun-Gyoo Lee, Sukjoong Oh, Seung-Sei Lee
The Korean Journal of Internal Medicine.2018; 33(3): 577. CrossRef
Endogenous Opiates and Behavior: 2015
Richard J. Bodnar
Peptides.2017; 88: 126. CrossRef
Drug Formulation Advances in Extended-Release Medications for Pain Control
Mark R. Jones, Martin J. Carney, Rachel J. Kaye, Amit Prabhakar, Alan D. Kaye
Current Pain and Headache Reports.2016;[Epub] CrossRef
The Clinical Applications of Extended-Release Abuse-Deterrent Opioids
Nalini Vadivelu, Erika Schermer, Gopal Kodumudi, Jack M. Berger
CNS Drugs.2016; 30(7): 637. CrossRef
Once-Daily OROS Hydromorphone for Management of Cancer Pain: an Open-Label, Multi-Center, Non-Interventional Study
Cheol Kyu Park, Hyun-Wook Kang, In-Jae Oh, Young-Chul Kim, Yeo-Kyeoung Kim, Kook-Joo Na, Sung-Ja Ahn, Tae Ok Kim, Young Jin Choi, Geun Am Song, Min Ki Lee
Journal of Korean Medical Science.2016; 31(12): 1914. CrossRef

13,142 View
81 Download
6 Crossref

Efficacy and Safety of Everolimus in Korean Patients with Metastatic Renal Cell Carcinoma Following Treatment Failure with a Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: Kwonoh Park, Jae-Lyun Lee, Jin-Hee Ahn, Kyoo Hyung Lee, In-Gab Jeong, Cheryn Song, Bumsik Hong, Jun Hyuk Hong, Hanjong Ahn; Cancer Res Treat. 2014;46(4):339-347. Published online July 16, 2014; DOI: https://doi.org/10.4143/crt.2013.154

Abstract PDF PubReader ePub

Purpose
The purpose of this study is to assess the efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma (mRCC) for whom initial treatment with a vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) has failed. Materials and Methods Eligible patients with mRCC (any histology) who had progressed on or were intolerant of VEGFr-TKI therapy received oral everolimus (10 mg dose once daily). Tumor response was reassessed according to Response Evaluation Criteria in Solid Tumors (RECIST). Results This study included 100 patientswith a median follow-up duration of 10.2 months, a median progression-free survival (PFS) of 4.2 months (95% confidence interval [CI], 3.4 to 5.0 months), and an overall survival of 10.1 months (95% CI, 6.9 to 13.3 months). The most common grade 3 or greater adverse events (AEs) overall were anemia (13%), pneumonitis (9%), hyperglycemia (8%), and stomatitis (6%). While the incidence of pneumonitis was similar (26 cases, 26%) to the reported incidence in Western patients, the Korean presentations were more severe: 10 patients permanently discontinued everolimus due to pneumonitis, including two deaths on treatment. Statistically significant relationships were established between biologic toxicities, hyperglycemia and anemia, and PFS (hyperglycemia vs. non-hyperglycemia: hazard ratio [HR], 0.61; p=0.055 and anemia vs. non-anemia: HR, 0.51; p=0.021). Conclusion Everolimus was effective in Korean patients with mRCC who had failed initial VEGFr-TKI therapy. While everolimus was well tolerated in general and the AE incidence of this study was similar to those of previous reports, severe pneumonitis was common. Hyperglycemia and anemia showed significant correlation with PFS and thus may be potentially useful as prognostic indicators.

Citations

Citations to this article as recorded by

Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor
Veronica Mollica, Vincenzo Di Nunno, Lidia Gatto, Matteo Santoni, Marina Scarpelli, Alessia Cimadamore, Antonio Lopez-Beltran, Liang Cheng, Nicola Battelli, Rodolfo Montironi, Francesco Massari
Cancers.2019; 11(6): 830. CrossRef
Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients
L Lo Muzio, C Arena, G Troiano, A Villa
Oral Diseases.2018; 24(1-2): 144. CrossRef

12,324 View
73 Download
5 Web of Science
2 Crossref

Multicenter Validation Study of a Prognostic Index for Portal Vein Tumor Thrombosis in Hepatocellular Carcinoma: Jeong Il Yu, Sang Min Yoon, Hee Chul Park, Jong Hoon Kim, Tae Hyun Kim, Joong-Won Park, Jinsil Seong, Ik Jae Lee, Hong Seok Jang, Chul Seung Kay, Chul Yong Kim, Eui Kyu Chie, Jin Hee Kim, Mi-Sook Kim, Young Min Choi; Cancer Res Treat. 2014;46(4):348-357. Published online July 16, 2014; DOI: https://doi.org/10.4143/crt.2013.142

Abstract PDF PubReader ePub

Purpose
We previously reported on a staging system and prognostic index (PITH) for portal vein tumor thrombosis (PVTT) in hepatocellular carcinoma (HCC) patients treated with radiotherapy (RT) at a single institution. The aim of this study is to validate the PITH staging system using data from patients at other institutions and to compare it with other published staging systems. Materials and Methods A total of 994 HCC patients with PVTT who were treated with RT between 1998 and 2011 by the Korean Radiation Oncology Group were analyzed retrospectively. All patients were staged using the Cancer of the Liver Italian Program (CLIP), Japanese Integrated Staging (JIS), Okuda, and PITH staging systems, and survival data were analyzed. The likelihood ratio, Akaike information criteria (AIC), time-dependent receiver operating characteristics, and prediction error curve analysis were used to determine discriminatory ability for comparison of staging systems. Results The median survival was 9.2 months. Compared with the other staging systems, the PITH score gave the highest values for likelihood ratio and lowest AIC values, demonstrating that PITH may be a better prognostic model. Although the values were not significant and differences were not exceptional, the PITH score showed slightly better performance with respect to time-dependent area under curve and integrated Brier score of prediction error curve. Conclusion The PITH staging system was validated in this multicenter retrospective study and showed better stratification ability in HCC patients with PVTT than other systems.

Citations

Citations to this article as recorded by

Efficacy and safety of radiotherapy combined with atezolizumab plus bevacizumab in treating hepatocellular carcinoma with portal vein tumour thrombus: a study protocol
Kang Wang, Hong-Ming Yu, Yan-Jun Xiang, Yu-Qiang Cheng, Qian-Zhi Ni, Wei-Xing Guo, Jie Shi, Shuang Feng, Jian Zhai, Shu-Qun Cheng
BMJ Open.2022; 12(12): e064688. CrossRef
Comparison of Transcatheter Arterial Chemoembolization-Radiofrequency Ablation and Transcatheter Arterial Chemoembolization Alone for Advanced Hepatocellular Carcinoma with Macrovascular Invasion Using Propensity Score Analysis: A Retrospective Cohort Stu
Yao Liu, Yuxin Li, Fangyuan Gao, Qun Zhang, Xue Yang, Bingbing Zhu, Shuaishuai Niu, Yunyi Huang, Ying Hu, Wei Li, Xianbo Wang
Journal of Oncology.2020; 2020: 1. CrossRef
2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
KLCA Korean Liver Cancer Association, NCC National Cancer Center
Gut and Liver.2019; 13(3): 227. CrossRef
2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

Korean Journal of Radiology.2019; 20(7): 1042. CrossRef
Outcome of transarterial chemoembolization in Egyptian patients with hepatocellular carcinoma and branch portal vein thrombosis
H. Abdella, M. K. Shaker, Iman Fawzy Montasser, M. Sobhi, H. Aly, A. Sayed, S. Saleh, A. El Dorry
Indian Journal of Gastroenterology.2018; 37(2): 127. CrossRef
Strategic application of radiotherapy for hepatocellular carcinoma
Seo Hee Choi, Jinsil Seong
Clinical and Molecular Hepatology.2018; 24(2): 114. CrossRef
Proton therapy for hepatocellular carcinoma: Current knowledges and future perspectives
Gyu Sang Yoo, Jeong Il Yu, Hee Chul Park
World Journal of Gastroenterology.2018; 24(28): 3090. CrossRef
Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis
Jeong Il Yu, Hee Chul Park
World Journal of Gastroenterology.2016; 22(30): 6851. CrossRef
Radiotherapy for liver tumors
Florence K Keane, Shyam K Tanguturi, Andrew X Zhu, Laura A Dawson, Theodore S Hong
Hepatic Oncology.2015; 2(2): 133. CrossRef
New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis
Hyun Young Woo, Jeong Heo
Clinical and Molecular Hepatology.2015; 21(2): 115. CrossRef
Current management of hepatocellular carcinoma: An Eastern perspective
Hyung Joon Yim
World Journal of Gastroenterology.2015; 21(13): 3826. CrossRef
Portal vein thrombosis: What is new?
María del Carmen Manzano-Robleda, Beatriz Barranco-Fragoso, Misael Uribe, Nahum Méndez-Sánchez
Annals of Hepatology.2015; 14(1): 20. CrossRef

13,941 View
71 Download
12 Web of Science
12 Crossref

Clinical Outcome of Relapsed or Refractory Burkitt Lymphoma and Mature B-Cell Lymphoblastic Leukemia in Children and Adolescents: Hyery Kim, Eun Sil Park, Soo Hyun Lee, Hong Hoe Koo, Hyo Sun Kim, Chuhl Joo Lyu, So Eun Jun, Young Tak Lim, Hee Jo Baek, Hoon Kook, Ji Won Lee, Hyoung Jin Kang, Kyung Duk Park, Hee Young Shin, Hyeo Seop Ahn; Cancer Res Treat. 2014;46(4):358-365. Published online July 21, 2014; DOI: https://doi.org/10.4143/crt.2013.047

Abstract PDF PubReader ePub

Purpose
Despite the rapid improvement in survival rate from Burkitt lymphoma and mature B-cell lymphoblastic leukemia (B-ALL) in children, a small subset of patients do not respond to first-line chemotherapy or experience relapse (RL). Herein, we report the clinical characteristics and outcomes of these patients.
Materials and Methods
RL or refractory Burkitt lymphoma and mature B-ALL in 125 patients diagnosed from 1990 to 2009 were retrospectively analyzed.
Results
Nineteen patients experienced RL or progressive disease (PD). Among them, 12 patients had PD or RL less than six months after initial treatment and seven had late RL. Seven patients achieved complete response (CR), 11 had PD, and one had no more therapy. Six patients who achieved CR survived without evidence of disease and four of them underwent high-dose chemotherapy (HDC) followed by stem cell transplantation (SCT). However, 11 patients who failed to obtain CR eventually died of their disease. Five-year overall survival (OS) was 31.6±10.7%. OS of patients with late RL was superior to that of patients with early RL (57.1±18.7%, vs. 16.7±10.8%, p=0.014). Achievement of CR after reinduction had significant OS (p < 0.001). OS for patients who were transplanted was superior (p < 0.01). In multivariate analysis, achievement of CR after reinduction chemotherapy showed an association with improved OS (p=0.05).
Conclusion
Late RL and chemotherapy-sensitive patients have the chance to achieve continuous CR using HDC/SCT, whereas patients who are refractory to retrieval therapy have poor prognosis. Therefore, novel salvage strategy is required for improvement of survival for this small set of patients.

Citations

Citations to this article as recorded by

The experience of relapsed Burkitt lymphoma treatment with targeted drugs and autologous/allogeneic stem cell transplantation
T. T. Valiev, A. A. Khachatryan, S. V. Goryacheva, N. A. Batmanova, K. I. Kirgizov, S. R. Varfolomeeva
Oncohematology.2024; 19(1): 40. CrossRef
Refractory Burkitt Lymphoma: Diagnosis and Interventional Strategies
Francesco Malfona, Anna Maria Testi, Sabina Chiaretti, Maria Luisa Moleti
Blood and Lymphatic Cancer: Targets and Therapy.2024; Volume 14: 1. CrossRef
MYC upstream region orchestrates resistance to PI3K inhibitors in cancer cells through FOXO3a-mediated autophagic adaptation
Rosa Bordone, Devon Michael Ivy, Rodrigo D’Amico, Martina Barba, Miriam Gaggianesi, Fiorella Di Pastena, Bianca Cesaro, Francesca Bufalieri, Alessio Balzerano, Enrico De Smaele, Giuseppe Giannini, Lucia Di Marcotullio, Alessandro Fatica, Giorgio Stassi, L
Oncogene.2024; 43(46): 3349. CrossRef
Prognostic Factors and Treatment Outcome of Relapsing and Refractory Pediatric Mature B-cell Non-Hodgkin Lymphoma, Children’s Cancer Hospital Egypt Experience
Samah F. Semary, Hany Abdel Rahman, Naglaa Elkinaai, Iman Zaky, Nouran Nagy, Sherine Salem, Asmaa Hamoda
Journal of Pediatric Hematology/Oncology.2023; 45(6): e757. CrossRef
Chronic Recurrent Multifocal Osteomyelitis Associated With Inflammatory Bowel Disease Successfully Treated With Infliximab
Shinhyeung Kwak, Dongsub Kim, Joon-sik Choi, Yoonsun Yoon, Eun Sil Kim, Mi Jin Kim, So-Young Yoo, Jong Sup Shim, Yon Ho Choe, Yae-Jean Kim
Pediatric Infection & Vaccine.2022; 29(2): 96. CrossRef
Burkitt lymphoma
Cristina López, Birgit Burkhardt, John K. C. Chan, Lorenzo Leoncini, Sam M. Mbulaiteye, Martin D. Ogwang, Jackson Orem, Rosemary Rochford, Mark Roschewski, Reiner Siebert
Nature Reviews Disease Primers.2022;[Epub] CrossRef
Efficacy and Safety of Inotuzumab Ozogamicin (CMC-544) for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis
Xueqian Li, Meng Zhou, Jiaqian Qi, Yue Han
Clinical Lymphoma Myeloma and Leukemia.2021; 21(3): e227. CrossRef
Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations
Birgit Burkhardt, Mary Taj, Nathalie Garnier, Veronique Minard-Colin, Volkan Hazar, Karin Mellgren, Tomoo Osumi, Alina Fedorova, Natalia Myakova, Jaime Verdu-Amoros, Mara Andres, Edita Kabickova, Andishe Attarbaschi, Alan Kwok Shing Chiang, Eva Bubanska,
Cancers.2021; 13(9): 2075. CrossRef
Long non-coding RNAs as the critical regulators of doxorubicin resistance in tumor cells
Ghazaleh Khalili-Tanha, Meysam Moghbeli
Cellular & Molecular Biology Letters.2021;[Epub] CrossRef
EBV BCL-2 homologue BHRF1 drives chemoresistance and lymphomagenesis by inhibiting multiple cellular pro-apoptotic proteins
Leah Fitzsimmons, Rachel Cartlidge, Catherine Chang, Nenad Sejic, Laura C. A. Galbraith, Chathura D. Suraweera, Deborah Croom-Carter, Grant Dewson, Rosemary J. Tierney, Andrew I. Bell, Clare Shannon-Lowe, Marco J. Herold, Alan B. Rickinson, Peter M. Colma
Cell Death & Differentiation.2020; 27(5): 1554. CrossRef
Treatment of relapsed/refractory paediatric aggressive B‐cell non‐Hodgkin lymphoma
Maria L. Moleti, Anna M. Testi, Robin Foà
British Journal of Haematology.2020; 189(5): 826. CrossRef
Clinical Characteristics and Treatment Outcomes of Pediatric Patients with Non-Hodgkin Lymphoma in East Asia
Jin Kyung Suh, Yi-Jin Gao, Jing-Yan Tang, Shiann-Tarng Jou, Dong-Tsamn Lin, Yoshiyuki Takahashi, Seiji Kojima, Ling Jin, Yonghong Zhang, Jong Jin Seo
Cancer Research and Treatment.2020; 52(2): 359. CrossRef
An 8-year retrospective study of adult and paediatric Burkitt’s lymphoma at Tygerberg Hospital, South Africa
Ernest Musekwa, Zivanai C. Chapanduka, Fatima Bassa, Mariana Kruger
South African Journal of Oncology.2020;[Epub] CrossRef
Rituximab is highly effective in children and adolescents with Burkitt lymphoma in Risk Groups R2 to R4
Zijun Zhen, Jia Zhu, Juan Wang, Suying Lu, Feifei Sun, Junting Huang, Xiaofei Sun
Pediatric Hematology and Oncology.2020; 37(6): 489. CrossRef
Knockdown of lncRNA MCM3AP-AS1 Attenuates Chemoresistance of Burkitt Lymphoma to Doxorubicin Treatment via Targeting the miR-15a/EIF4E Axis

Chao Guo, Ming Gong, Zhenling Li
Cancer Management and Research.2020; Volume 12: 5845. CrossRef
Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Kimberly Davies, Matthew Barth, Saro Armenian, Anthony N. Audino, Phillip Barnette, Branko Cuglievan, Hilda Ding, James B. Ford, Paul J. Galardy, Rebecca Gardner, Rabi Hanna, Robert Hayashi, Alexandra E. Kovach, Andrea Judit Machnitz, Kelly W. Maloney, Li
Journal of the National Comprehensive Cancer Network.2020; 18(8): 1105. CrossRef
Hematopoietic stem cell transplantation in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma
Naoto Fujita, Ryoji Kobayashi, Yoshiko Atsuta, Fuminori Iwasaki, Junji Suzumiya, Yoji Sasahara, Masami Inoue, Katsuyoshi Koh, Tsukasa Hori, Hiroaki Goto, Tatsuo Ichinohe, Yoshiko Hashii, Koji Kato, Ritsuro Suzuki, Tetsuo Mitsui
International Journal of Hematology.2019; 109(4): 483. CrossRef
An update on Burkitt lymphoma: a review of pathogenesis and multimodality imaging assessment of disease presentation, treatment response, and recurrence
Kevin Kalisz, Francesco Alessandrino, Rose Beck, Daniel Smith, Elias Kikano, Nikhil H. Ramaiya, Sree Harsha Tirumani
Insights into Imaging.2019;[Epub] CrossRef
Unusual lymphoid malignancy and treatment response in two children with Down syndrome
Ashley Geerlinks, Jennifer Keis, Bo Ngan, Amer Shammas, Reza Vali, Johann Hitzler
Pediatric Blood & Cancer.2019;[Epub] CrossRef
Outcome of relapse in children and adolescents with B‐cell non‐Hodgkin lymphoma and mature acute leukemia: A report from the French LMB study
Charlotte Rigaud, Anne Auperin, Anne Jourdain, Stephanie Haouy, Marie‐Laure Couec, Nathalie Aladjidi, Virginie Gandemer, Anne Lambliotte, Geneviève Plat, Judith Landman‐Parker, Jean Michon, Thierry Leblanc, Catherine Patte, Veronique Minard‐Colin
Pediatric Blood & Cancer.2019;[Epub] CrossRef
Anti-Tumor Effect of a Novel DOX/GA-CdTe QD was Mediated by Apoptotic and Autophagic Cell Death
Huaqin Zuo, Fan Wang, Di Zhou, Yi Zhou, Bing Chen, Jian Ouyang, Peipei Xu
Nano.2017; 12(01): 1750011. CrossRef
Immunotherapy with the trifunctional anti-CD20 × anti-CD3 antibody FBTA05 in a patient with relapsed t(8;14)-positive post-transplant lymphoproliferative disease
Anna Kieslich, Peter Ruf, Horst Lindhofer, Raynold Buhmann, Angelika Eggert, Patrick Hundsdoerfer
Leukemia & Lymphoma.2017; 58(8): 1989. CrossRef
Outcomes of adults with relapsed or refractory Burkitt and high‐grade B‐cell leukemia/lymphoma
Nicholas J. Short, Hagop M. Kantarjian, Heidi Ko, Joseph D. Khoury, Farhad Ravandi, Deborah A. Thomas, Guillermo Garcia‐Manero, Maria Khouri, Jorge E. Cortes, William G. Wierda, Srdan Verstovsek, Zeev Estrov, Alessandra Ferrajoli, Philip A. Thompson, Sher
American Journal of Hematology.2017;[Epub] CrossRef

16,074 View
194 Download
23 Crossref

Clinical Characteristics and Adequate Treatment of Familial Adenomatous Polyposis Combined with Desmoid Tumors: Won Beom Jung, Chan Wook Kim, Jin Cheon Kim; Cancer Res Treat. 2014;46(4):366-373. Published online August 25, 2014; DOI: https://doi.org/10.4143/crt.2013.185

Abstract PDF PubReader ePub

Purpose
The objective of this study was to examine the clincopathologic characteristics and outcomes of familial adenomatous polyposis (FAP) patients with and without desmoid tumors (DTs), including the risk factors for progression of FAP-related DTs. Materials and Methods We reviewed the medical records and database of all patients with FAP who were treated between January 1993 and December 2011. Results Of 75 FAP patients, 18 (24%) were FAP with DTs. Seventeen of these had intra-abdominal DTs and one had intra- and extra-abdominal DTs. We divided the patients into two groups according to type of resection; the R0 or R1 resection group, referred to as the curative resection group (eight patients), and the R2 resection/palliative operation/medical treatment group, referred to as the palliative resection group (10 patients). Two patients in the curative resection group and two patients in the palliative group had progressed to tumor growth by the follow-up (p=0.800). In univariate analysis, DT diagnosis before or simultaneously with FAP diagnosis (DTs unrelated to surgical trauma) was a significant risk factor for tumor progression at final follow-up. Conclusion A multidisciplinary approach to DT treatment is needed, including nonsteroidal antiinflammatory drugs, anti-estrogens, cytotoxic agents, and surgery. However, the role of surgery in resectable and complicated tumors may be limited. DT unrelated to surgical trauma has a relatively poor prognosis.

Citations

Citations to this article as recorded by

The language of palliative surgery: A scoping review
K.E. Kopecky, O. Monton, C. Arbaugh, J. Purchla, L. Rosman, S. Seal, F.M. Johnston
Surgical Oncology Insight.2024; 1(2): 100053. CrossRef
Adenomatous Polyposis Coli Gene Mutations, Risk Factors, and Long-term Outcomes Associated With Desmoid Tumors in Patients With Familial Adenomatous Polyposis After Colectomy in Japan
Tadahiro Kojima, Kiyotaka Kurachi, Moriya Iwaizumi, Kyota Tatsuta, Kosuke Sugiyama, Toshiya Akai, Mayu Sakata, Yoshifumi Morita, Hirotoshi Kikuchi, Yoshihiro Hiramatsu, Hiroya Takeuchi
Journal of Clinical Gastroenterology.2024;[Epub] CrossRef
Giant desmoid tumour mimicking recurrent uterine myoma in a nulliparous young Nigerian: a case report
Obinna Chukwunwike Njoku, Chisara Cyprian Umezurike
Journal of Medical Case Reports.2022;[Epub] CrossRef
Entirely Robot-assisted Total Colectomy/Total Proctocolectomy Compared With a Laparoscopic Approach
Jin Cheon Kim, Jong Lyul Lee, Yong Sik Yoon, Hyung Min Kim, Chan Wook Kim, In Ja Park, Abdulmohsin Fawzi Aldilaijan, Seok-Byung Lim
Surgical Laparoscopy, Endoscopy & Percutaneous Techniques.2021; 31(4): 428. CrossRef
Caring for a patient with a desmoid tumor
Janette O'Sullivan, Margaret Vanderbeek-Warren
Nursing.2018; 48(6): 27. CrossRef
Genetic profile, risk factors and therapeutic approach of desmoid tumors in familial adenomatous polyposis
Ana Catarina Ribeiro Freitas, Laura Elisabete Ribeiro Barbosa
Journal of Coloproctology.2017; 37(02): 163. CrossRef
Tumeurs desmoïdes dans le cadre d’une polypose adénomateuse familiale chez une adolescente
M. Creuzé, P. Afchain, A. Munck, J. Viala, A. Bonnard, V. Bertrand
Archives de Pédiatrie.2016; 23(11): 1141. CrossRef
Clinicopathological features of familial adenomatous polyposis in Korean patients
Sung Min Jung, Yong Sik Yoon, Seok-Byeong Lim, Chang Sik Yu, Jin Cheon Kim
World Journal of Gastroenterology.2016; 22(17): 4380. CrossRef
Commentary on “Clinical Characteristics and Adequate Treatment of Familial Adenomatous Polyposis Combined with Desmoid Tumors”
Edoardo Virgilio, Francesca Di Gregorio, Genoveffa Balducci
Cancer Research and Treatment.2015; 47(2): 339. CrossRef
Reply to Commentary on “Clinical Characteristics and Adequate Treatment of Familial Adenomatous Polyposis Combined with Desmoid Tumors”
Jin Cheon Kim
Cancer Research and Treatment.2015; 47(2): 341. CrossRef
Optimal therapy for desmoid tumors: current options and challenges for the future
Mushriq Al-Jazrawe, Magdalene Au, Benjamin Alman
Expert Review of Anticancer Therapy.2015; 15(12): 1443. CrossRef

12,566 View
79 Download
9 Web of Science
11 Crossref

Is Prophylactic Irradiation to Para-aortic Lymph Nodes in Locally Advanced Cervical Cancer Necessary?: Seung Gyu Park, Jin Hee Kim, Young Kee Oh, Sang Jun Byun, Mi Young Kim, Sang Hoon Kwon, Ok Bae Kim; Cancer Res Treat. 2014;46(4):374-382. Published online July 21, 2014; DOI: https://doi.org/10.4143/crt.2013.084

Abstract PDF PubReader ePub

Purpose
This study evaluated the efficacy of extended field irradiation (EFI) in patients with locally advanced cervical cancer without para-aortic nodal involvement.
Materials and Methods
A total of 203 patients with locally advanced cervical cancer (International Federation of Gynecology and Obstetrics [FIGO] stage, IB2-IIIB) treated with radiotherapy at Keimyung University Dongsan Medical Center from 1996 to 2010 were retrospectively analyzed. The median patient age was 59 years (range, 29 to 83 years). None of the patients had para-aortic node metastases. Of the 203 patients, 88 underwent EFI and 115 underwent irradiation of the pelvis only. Concurrent chemoradiotherapy (CCRT) was administered to 133 patients. EFI field was used for treatment of 26 patients who received radiotherapy alone and 62 who received CCRT.
Results
The median follow-up period was 60 months. The 2- and 5-year overall survival (OS) rates were 87.8% and 73.5%, respectively, and the 2- and 5-year disease-free survival rates were 81.7% and 75.0%, respectively, however, no survival differences were observed between the two treatment field groups. EFI tended to increase OS in the radiotherapy alone group, but not in the CCRT group.
Conclusion
These findings suggest that EFI does not have a significant effect in patients with locally advanced cervical cancer, especially in patients receiving CCRT. Conduct of additional studies will be required in order to confirm these findings.

Citations

Citations to this article as recorded by

Clinical analysis of prophylactic para-aortic intensity-modulated radiation in cervical cancer
G. Jin, K. Li, S. Niu, S. Liu, Q. Zhang, X. Fan
Clinical Radiology.2023; 78(2): e77. CrossRef
Combined modality management of advanced cervical cancer including novel sensitizers
Michelle Tseng, Natalie YL Ngoi, David SP Tan, Pearl SY Tong
International Journal of Gynecologic Cancer.2022; 32(3): 246. CrossRef
The best postoperative adjuvant therapy for patients with early stage cervical adenosquamous carcinoma
Yawen Liu, Haiyan Tu, Lingling Zhang, Meiling Zhong, Yanan Wang, Ling Li, Xiaojun Xiang
BMC Women's Health.2022;[Epub] CrossRef
The impact of para-aortic lymph node irradiation on disease-free survival in patients with cervical cancer: A systematic review and meta-analysis
Leslie J.H. Bukkems, Ina M. Jürgenliemk-Schulz, Femke van der Leij, Max Peters, Cornelis G. Gerestein, Ronald P. Zweemer, Peter S.N. van Rossum
Clinical and Translational Radiation Oncology.2022; 35: 97. CrossRef
Clinical impact of extended field radiation therapy in Stage III carcinoma cervix versus conventional field techniques
Prateek Daga, H. S. Kumar, Neeti Sharma, Shankar Lal Jakhar, Kamlesh Kumar Harsh, Saroj Dhaka
Journal of Cancer Research and Therapeutics.2022; 18(4): 1083. CrossRef
Patterns of definitive radiotherapy practice for cervical cancer in South Korea: a survey endorsed by the Korean Radiation Oncology Group (KROG 20-06)
Nalee Kim, Won Park
Journal of Gynecologic Oncology.2021;[Epub] CrossRef
Risk factors for nodal failure after radiochemotherapy and image guided brachytherapy in locally advanced cervical cancer: An EMBRACE analysis
Max Peters, Astrid A.C. de Leeuw, Christel N. Nomden, Kari Tanderup, Kathrin Kirchheiner, Jacob C. Lindegaard, Christian Kirisits, Christine Haie-Meder, Alina Sturdza, Lars Fokdal, Umesh Mahantshetty, Peter Hoskin, Barbara Segedin, Kjersti Bruheim, Bhavan
Radiotherapy and Oncology.2021; 163: 150. CrossRef
Higher Dose to Organs at Risk: The Unintended Consequences of Intravenous Contrast Use in Computed Tomography Simulation for Cervical Cancer
Dunhuang Wang, Bo Yang, Weiping Wang, Xiaoliang Liu, Yongguang Liang, Shuai Sun, Jiabin Ma, Bing Zhou, Ke Hu, Fuquan Zhang
Practical Radiation Oncology.2021; 11(6): 534. CrossRef
Lymphocytopenia and Radiotherapy Treatment Volumes in the Time of COVID-19
N. Joseph, A. Choudhury
Clinical Oncology.2020; 32(7): 420. CrossRef
Prophylactic Extended-Field Irradiation in Patients With Cervical Cancer: A Literature Review
Weiping Wang, Yuncan Zhou, Dunhuang Wang, Ke Hu, Fuquan Zhang
Frontiers in Oncology.2020;[Epub] CrossRef
Nomogram for predicting para-aortic lymph node metastases in patients with cervical cancer
Weiping Wang, Xiaoliang Liu, Qingyu Meng, Fuquan Zhang, Ke Hu
Archives of Gynecology and Obstetrics.2018; 298(2): 381. CrossRef
Prophylactic Extended-Field Irradiation for Patients With Cervical Cancer Treated With Concurrent Chemoradiotherapy: A Propensity-Score Matching Analysis
Weiping Wang, Xiaoliang Liu, Qingyu Meng, Fuquan Zhang, Ke Hu
International Journal of Gynecologic Cancer.2018; 28(8): 1584. CrossRef
The role of para-aortic nodal irradiation in cervical cancer
Adela Poitevin Chacón, Jessica Chavez-Nogueda, Rubí Ramos-Prudencio, Michelle Aline Villavicencio-Queijeiro, Francisco Lozano-Ruiz
Reports of Practical Oncology & Radiotherapy.2018; 23(6): 540. CrossRef
Management of Para-aortic Lymph Node Disease in Patients With Cervical Cancer
Marcelo Vailati Negrão, Julianne Maria da Silva Lima, Samantha Cabral Severino Silva, Maria Del Pilar Estevez Diz, Vanessa da Costa Miranda
International Journal of Gynecological Cancer.2017; 27(3): 543. CrossRef
Prophylactic extended-field irradiation with concurrent chemotherapy for pelvic lymph node-positive cervical cancer
Jinju Oh, Ki Ho Seol, Hyun Joo Lee, Youn Seok Choi, Ji Y. Park, Jin Young Bae
Radiation Oncology Journal.2017; 35(4): 349. CrossRef
Impact of primary para-aortic lymphadenectomy on distant failure in locally advanced cervical cancer patients treated in the era of image-guided adaptive brachytherapy
Cyrus Chargari, Renaud Mazeron, Ariane Dunant, Sébastien Gouy, Claire Petit, Pierre Maroun, Catherine Uzan, Pierre Annede, Enrica Bentivegna, Corinne Balleyguier, Catherine Genestie, Patricia Pautier, Alexandra Leary, Catherine Lhomme, Eric Deutsch, Phili
Clinical & Experimental Metastasis.2016; 33(8): 775. CrossRef
Optimal Extent of Prophylactic Irradiation of Paraaortic Lymph Nodes in Patients with Uterine Cervical Cancer
Jinhyun Choi, Hong In Yoon, Jeongshim Lee, Ki Chang Keum, Gwi Eon Kim, Yong Bae Kim, Ruby John Anto
PLOS ONE.2015; 10(12): e0145158. CrossRef

13,040 View
109 Download
17 Crossref

p27 Loss Is Associated with Poor Prognosis in Gastroenteropancreatic Neuroendocrine Tumors: Hee Sung Kim, Hye Seung Lee, Kyung Han Nam, Jiwoon Choi, Woo Ho Kim; Cancer Res Treat. 2014;46(4):383-392. Published online July 17, 2014; DOI: https://doi.org/10.4143/crt.2013.102

Abstract PDF PubReader ePub

Purpose
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) represent a heterogeneous disease group originating from the neuroendocrine cells. Identification of prognostic markers, related to neuroendocrine tissue-selective tumorigenesis, is necessary to find therapeutic targets.
Materials and Methods
A total of 327 patients with GEP-NETs were included in this study; there were 49 gastric, 29 duodenal, 49 pancreatic, 12 hepatobiliary, 33 appendiceal, 5 proximal colon, and 150 distal colon cases. We performed immunostaining with the tissue microarray method for menin, p27, and p18.
Results
We observed negative staining for menin, p27, and p18 in 34%, 21%, and 56% of GEP-NETs, respectively. The loss of p27, but not menin, was positively correlated with the grade of Ki-67. Menin–/p27–, menin–/p27+, menin+/p27–, and menin+/p27+ phenotype groups included 13%, 22%, 8%, and 57% of patients, respectively. A dichotomized comparison showed that menin– or p27– tumors were significantly associated with foregut and midgut localizations, high World Health Organization (WHO) grade, lymph node metastasis, and more advanced stage as compared to menin+/p27+ patients. Kaplan-Meier analysis for the overall survival showed that p27 loss was significantly associated with decreased survival. Multivariate analysis showed that p27 loss is an independent factor for poor overall survival.
Conclusion
Our results revealed that the loss of p27 is associated with poor prognosis and the menin-p27 pathway is important in the tumorigenesis of GEP-NETs.

Citations

Citations to this article as recorded by

Menin in Cancer
Ariana D. Majer, Xianxin Hua, Bryson W. Katona
Genes.2024; 15(9): 1231. CrossRef
Current Status of Immunotherapy in Management of Small Bowel Neuroendocrine Tumors
Brittany C. Fields, Reed I. Ayabe, Y. David Seo, Jessica E. Maxwell, Daniel M. Halperin
Current Oncology Reports.2024; 26(11): 1530. CrossRef
Status of Surveillance and Nonsurgical Therapy for Small Nonfunctioning Pancreatic Neuroendocrine Tumors
Dirk-Jan van Beek, Anna Vera D. Verschuur, Lodewijk A.A. Brosens, Gerlof D. Valk, Carolina R.C. Pieterman, Menno R. Vriens
Surgical Oncology Clinics of North America.2023; 32(2): 343. CrossRef
The link between menin and pleiotrophin in the tumor biology of pancreatic neuroendocrine neoplasms
Liping He, Steeve Boulant, Megan Stanifer, Cuncai Guo, Anna Nießen, Mingyi Chen, Klaus Felix, Frank Bergmann, Oliver Strobel, Simon Schimmack
Cancer Science.2022; 113(5): 1575. CrossRef
Recent advances in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms
Meng Dai, Christina S Mullins, Lili Lu, Guido Alsfasser, Michael Linnebacher
World Journal of Gastrointestinal Surgery.2022; 14(5): 383. CrossRef
A Machine Learning Decision Support System (DSS) for Neuroendocrine Tumor Patients Treated with Somatostatin Analog (SSA) Therapy
Jasminka Hasic Telalovic, Serena Pillozzi, Rachele Fabbri, Alice Laffi, Daniele Lavacchi, Virginia Rossi, Lorenzo Dreoni, Francesca Spada, Nicola Fazio, Amedeo Amedei, Ernesto Iadanza, Lorenzo Antonuzzo
Diagnostics.2021; 11(5): 804. CrossRef
The Role of Conventionally Fractionated Radiotherapy and Stereotactic Radiotherapy in the Treatment of Carcinoid Tumors and Large-Cell Neuroendocrine Cancer of the Lung
Mateusz Bilski, Paulina Mertowska, Sebastian Mertowski, Marcin Sawicki, Anna Hymos, Paulina Niedźwiedzka-Rystwej, Ewelina Grywalska
Cancers.2021; 14(1): 177. CrossRef
The molecular biology of pancreatic neuroendocrine neoplasms: Challenges and translational opportunities
Kate Young, Naureen Starling, Anguraj Sadanandam
Seminars in Cancer Biology.2020; 61: 132. CrossRef
Rb and p53 Execute Distinct Roles in the Development of Pancreatic Neuroendocrine Tumors
Yuki Yamauchi, Yuzo Kodama, Masahiro Shiokawa, Nobuyuki Kakiuchi, Saiko Marui, Takeshi Kuwada, Yuko Sogabe, Teruko Tomono, Atsushi Mima, Toshihiro Morita, Tomoaki Matsumori, Tatsuki Ueda, Motoyuki Tsuda, Yoshihiro Nishikawa, Katsutoshi Kuriyama, Yojiro Sa
Cancer Research.2020; 80(17): 3620. CrossRef
Signaling networks and the feasibility of computational analysis in gastroenteropancreatic neuroendocrine tumors
Pengchen Chen, Qingshui Wang, Jianwei Xie, Hang Fai Kwok
Seminars in Cancer Biology.2019; 58: 80. CrossRef
Reduced expression of the RNA‐binding protein HuD in pancreatic neuroendocrine tumors correlates with low p27Kip1 levels and poor prognosis
Chongtae Kim, Da Eun Jeong, Sungeun Heo, Eunbyul Ji, Jun Gi Rho, Myeongwoo Jung, Sojin Ahn, Ye‐Jin Kim, Yong‐Sung Kim, Suk Woo Nam, Rohit N Kulkarni, Kyoung Bun Lee, Eun Kyung Lee, Wook Kim
The Journal of Pathology.2018; 246(2): 231. CrossRef
Current Standards and Recent Advances in Biomarkers of Major Endocrine Tumors
Yanhong Luo, Hua Zhu, Tao Tan, Jianfeng He
Frontiers in Pharmacology.2018;[Epub] CrossRef
Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets
E T Aristizabal Prada, C J Auernhammer
Endocrine Connections.2018; 7(1): R1. CrossRef
Deletion ofMen1andsomatostatininduces hypergastrinemia and gastric carcinoids
Sinju Sundaresan, Anthony J Kang, Michael M Hayes, Eun-Young K Choi, Juanita L Merchant
Gut.2017; 66(6): 1012. CrossRef
Cell Cycle Protein Expression in Neuroendocrine Tumors
Yan Shi, Zhi Rong Qian, Sui Zhang, Wanwan Li, Yohei Masugi, Tingting Li, Jennifer A. Chan, Juhong Yang, Annacarolina Da Silva, Mancang Gu, Li Liu, Tsuyoshi Hamada, Keisuke Kosumi, Trevor Dutton, Lauren K. Brais, Reiko Nishihara, Charles S. Fuchs, Shuji Og
Pancreas.2017; 46(10): 1347. CrossRef
DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications
Iris H. Liu, James M. Ford, Pamela L. Kunz
Cancer Treatment Reviews.2016; 44: 1. CrossRef
Differential Protein Expression in Small Intestinal Neuroendocrine Tumors and Liver Metastases
Michelle Kang Kim, Fei Ye, Daguang Wang, Miao Cui, Stephen C. Ward, Richard R.P. Warner, Sasan Roayaie, Michail Shafir, Myron Schwartz, David Zhang, Steven Itzkowitz
Pancreas.2016; 45(4): 528. CrossRef
Expression profiling of small intestinal neuroendocrine tumors identifies subgroups with clinical relevance, prognostic markers and therapeutic targets
Ellinor Andersson, Yvonne Arvidsson, Christina Swärd, Tobias Hofving, Bo Wängberg, Erik Kristiansson, Ola Nilsson
Modern Pathology.2016; 29(6): 616. CrossRef
Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs
Robert Roskoski
Pharmacological Research.2016; 107: 249. CrossRef
Recent Updates on Neuroendocrine Tumors From the Gastrointestinal and Pancreatobiliary Tracts
Joo Young Kim, Seung-Mo Hong
Archives of Pathology & Laboratory Medicine.2016; 140(5): 437. CrossRef
Somatic Mutations and Genetic Heterogeneity at the CDKN1B Locus in Small Intestinal Neuroendocrine Tumors
Joakim Crona, Tobias Gustavsson, Olov Norlén, Katarina Edfeldt, Tobias Åkerström, Gunnar Westin, Per Hellman, Peyman Björklund, Peter Stålberg
Annals of Surgical Oncology.2015; 22(S3): 1428. CrossRef
Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status
Mark Kidd, Ignat Drozdov, Irvin Modlin
Endocrine-Related Cancer.2015; 22(4): 561. CrossRef

12,280 View
66 Download
26 Web of Science
22 Crossref

Ultra-Low-Dose Chest CT in Patients with Neutropenic Fever and Hematologic Malignancy: Image Quality and Its Diagnostic Performance: Hae Jin Kim, So Young Park, Ho Yun Lee, Kyung Soo Lee, Kyung Eun Shin, Jung Won Moon; Cancer Res Treat. 2014;46(4):393-402. Published online July 18, 2014; DOI: https://doi.org/10.4143/crt.2013.132

Abstract PDF PubReader ePub

Purpose
The aim of this study was to evaluate the image quality of ultra-low-dose CT (ULDCT) and its diagnostic performance in making a specific diagnosis of pneumonia in febrile neutropenic patients with hematological malignancy.
Materials and Methods
ULDCT was performed prospectively in 207 febrile neutropenic patients with hematological malignancy. Three observers independently recorded the presence of lung parenchymal abnormality, and also indicated the cause of the lung parenchymal abnormality between infectious and noninfectious causes. If infectious pneumonia was considered the cause of lung abnormalities, they noted the two most appropriate diagnoses among four infectious conditions, including fungal, bacterial, viral, and Pneumocystis pneumonia. Sensitivity for correct diagnoses and receiver operating characteristic (ROC) curve analysis for evaluation of diagnostic accuracy were calculated. Interobserver agreements were determined using intraclass correlation coefficient (ICC).
Results
Of 207 patients, 139 (67%) had pneumonia, 12 had non-infectious lung disease, and 56 had no remarkable chest CT (20 with extra-thoracic fever focus and 36 with no specific disease). Mean radiation expose dose of ULDCT was 0.60 ± 0.15 mSv. Each observer regarded LDCT scans as unacceptable in only four (1.9%), one (0.5%), and three (1.5%) cases of ULDCTs. Sensitivity and area under the ROC curve in making a specific pneumonia diagnosis were 63.0%, 0.65 for reader 1, 63.0%, 0.61 for reader 2, and 65.0%, 0.62 for reader 3, respectively.
Conclusions
ULDCT, with a sub-mSv radiation dose and acceptable image quality, provides ready and reasonably acceptable diagnostic information for pulmonary infection in febrile neutropenic patients with hematologic malignancy.

Citations

Citations to this article as recorded by

The diagnostic utility of computed tomography scans performed for febrile neutropenia in a single centre
Victor K.O. Chang, Ee Shern Liang, Paul Schmidt
Current Problems in Diagnostic Radiology.2024; 53(3): 341. CrossRef
Diagnostic Accuracy in Detecting Fungal Infection with Ultra-Low-Dose Computed Tomography (ULD-CT) Using Filtered Back Projection (FBP) Technique in Immunocompromised Patients
Luigia D’Errico, Anita Ghali, Mini Pakkal, Micheal McInnis, Hatem Mehrez, Andre C. Schuh, John G. Kuruvilla, Mark Minden, Narinder S. Paul
Journal of Clinical Medicine.2024; 13(6): 1704. CrossRef
The Differential Diagnostic Value of Chest Computed Tomography for the Identification of Pathogens Causing Pulmonary Infections in Patients with Hematological Malignancies
Qian Cheng, Yishu Tang, Jing Liu, FeiYang Liu, Xin Li
Infection and Drug Resistance.2024; Volume 17: 4557. CrossRef
Sequential low-dose CT thorax scans to determine invasive pulmonary fungal infection incidence after allogeneic hematopoietic cell transplantation
K. Enger, X. Tonnar, E. Kotter, H. Bertz
Annals of Hematology.2023; 102(2): 413. CrossRef
The Use of Low-Dose Chest Computed Tomography for the Diagnosis and Monitoring of Pulmonary Infections in Patients with Hematologic Malignancies
Efthimios Agadakos, Alexandra Zormpala, Nikolaos Zaios, Chrysoula Kapsiocha, Maria N. Gamaletsou, Michael Voulgarelis, Nikolaos V. Sipsas, Lia Angela Moulopoulos, Vassilis Koutoulidis
Cancers.2023; 16(1): 186. CrossRef
Chest CT Has Higher Yield for Infection than CT Sinus in Febrile Neutropenic Patients
Won Kyu Choi, Adam D'Sa, Joseph N. Holman, Samrah Javed, Sarah Thompson, Rohini N. Nadgir
Current Problems in Diagnostic Radiology.2022; 51(3): 340. CrossRef
Time to Scrutinize and Revise the Fine Print of Lung Cancer Screening Using Low-Dose CT: Seeking Greater Confidence in Cancer Detectability
Ho Yun Lee
Radiology.2022; 303(1): 213. CrossRef
Pleuro-pulmonary ultrasound in the diagnosis and follow-up of lung infections in children with cancer: a pilot study
Mariaclaudia Meli, Milena La Spina, Luca Lo Nigro, Gian Luca Trobia, Giovanna Russo, Andrea Di Cataldo
Journal of Ultrasound.2022; 25(4): 865. CrossRef
A Review of Current Knowledge for X-ray Energy in CT: Practical Guide for CT Technologist
Kazutaka Hoyoshi, Tomomi Ohmura, Shingo Kayano, Mitsunori Goto, Shun Muramatsu, Noriyasu Homma
Japanese Journal of Radiological Technology.2022; 78(5): 449. CrossRef
Diagnostic Utility of Bronchoalveolar Lavage in Patients with Acute Leukemia under Broad-Spectrum Anti-Infective Treatment
Susanne Ghandili, Philipp H. von Kroge, Marcel Simon, Frank O. Henes, Holger Rohde, Armin Hoffmann, Nick Benjamin Lindeman, Carsten Bokemeyer, Walter Fiedler, Franziska Modemann
Cancers.2022; 14(11): 2773. CrossRef
New approaches to management of fever and neutropenia in high-risk patients
Abby Douglas, Karin Thursky, Monica Slavin
Current Opinion in Infectious Diseases.2022; 35(6): 500. CrossRef
Guidance on Imaging for Invasive Pulmonary Aspergillosis and Mucormycosis: From the Imaging Working Group for the Revision and Update of the Consensus Definitions of Fungal Disease from the EORTC/MSGERC
Barbara D Alexander, Frédéric Lamoth, Claus Peter Heussel, Cornelia Schaefer Prokop, Sujal R Desai, C Orla Morrissey, John W Baddley
Clinical Infectious Diseases.2021; 72(Supplement): S79. CrossRef
Early low-dose computed tomography with pulmonary angiography to improve the early diagnosis of invasive mould disease in patients with haematological malignancies: A pilot study
Marta Stanzani, Claudia Sassi, Russell Lewis, Chiara Sartor, Gianluca Rasetto, Michele Cavo, Giuseppe Battista
Journal of Infection.2021; 83(3): 371. CrossRef
Impact of Morphotype on Image Quality and Diagnostic Performance of Ultra-Low-Dose Chest CT
Anne-Claire Ortlieb, Aissam Labani, François Severac, Mi-Young Jeung, Catherine Roy, Mickaël Ohana
Journal of Clinical Medicine.2021; 10(15): 3284. CrossRef
The results of approbation of a comprehensive expert assessment of the quality of CT images of the chest obtained on low-dose scanning protocols using iterative reconstruction methods
G. V. Berkovich, A. V. Vodovatov, L. A. Chipiga, G. E. Trufanov
Diagnostic radiology and radiotherapy.2021; 12(3): 54. CrossRef
Detection of secondary causes of spontaneous pneumothorax: Comparison between computed tomography and chest X-ray
A.M. Ruppert, D. Sroussi, A. Khallil, M. Giot, J. Assouad, J. Cadranel, V. Gounant
Diagnostic and Interventional Imaging.2020; 101(4): 217. CrossRef
Ultra-low-dose unenhanced chest CT: Prospective comparison of high kV/low mA versus low kV/high mA protocols
C. Ludes, A. Labani, F. Severac, M.Y. Jeung, P. Leyendecker, C. Roy, M. Ohana
Diagnostic and Interventional Imaging.2019; 100(2): 85. CrossRef
Added Value of Ultra–low-dose Computed Tomography, Dose Equivalent to Chest X-Ray Radiography, for Diagnosing Chest Pathology
Lucia J.M. Kroft, Levinia van der Velden, Irene Hernández Girón, Joost J.H. Roelofs, Albert de Roos, Jacob Geleijns
Journal of Thoracic Imaging.2019; 34(3): 179. CrossRef
Differential diagnosis of pulmonary infections in immunocompromised patients using high-resolution computed tomography
Yoshie Kunihiro, Nobuyuki Tanaka, Reo Kawano, Toshiaki Yujiri, Makoto Kubo, Kazuhiro Ueda, Toshikazu Gondo, Taiga Kobayashi, Tsuneo Matsumoto
European Radiology.2019; 29(11): 6089. CrossRef
Wide-volume versus helical acquisition in unenhanced chest CT: prospective intra-patient comparison of diagnostic accuracy and radiation dose in an ultra-low-dose setting
Elsa Meyer, Aissam Labani, Mickaël Schaeffer, Mi-Young Jeung, Claire Ludes, Alain Meyer, Catherine Roy, Pierre Leyendecker, Mickaël Ohana
European Radiology.2019; 29(12): 6858. CrossRef
OPTimal IMAging strategy in patients suspected of non-traumatic pulmonary disease at the emergency department: chest X-ray or ultra-low-dose CT (OPTIMACT)—a randomised controlled trial chest X-ray or ultra-low-dose CT at the ED: design and rationale
Inge A. H. van den Berk, Maadrika M. N. P. Kanglie, Tjitske S. R. van Engelen, Shandra Bipat, Marcel G. W. Dijkgraaf, Patrick M. M. Bossuyt, Wouter de Monyé, Jan M. Prins, Jaap Stoker
Diagnostic and Prognostic Research.2018;[Epub] CrossRef
Infection in Immunocompromised Hosts: Imaging
Nobuyuki Tanaka, Yoshie Kunihiro, Noriyo Yanagawa
Journal of Thoracic Imaging.2018; 33(5): 306. CrossRef
Quel avenir pour la radiographie thoracique face au scanner ultra-low dose ?
M. Ohana, C. Ludes, M. Schaal, E. Meyer, M.-Y. Jeung, A. Labani, C. Roy
Revue de Pneumologie Clinique.2017; 73(1): 3. CrossRef
Improving early diagnosis of pulmonary infections in patients with febrile neutropenia using low-dose chest computed tomography
M. G. Gerritsen, M. J. Willemink, E. Pompe, T. van der Bruggen, A. van Rhenen, J. W. J. Lammers, F. Wessels, R. W. Sprengers, P. A. de Jong, M. C. Minnema, Scott G. Filler
PLOS ONE.2017; 12(2): e0172256. CrossRef
In the Literature

Clinical Infectious Diseases.2017; 64(6): iii. CrossRef
Bacterial Pneumonia in Patients with Cancer
Justin L. Wong, Scott E. Evans
Clinics in Chest Medicine.2017; 38(2): 263. CrossRef
Diagnosis and management ofPneumocystis jiroveciiinfection
P. Lewis White, Matthijs Backx, Rosemary A. Barnes
Expert Review of Anti-infective Therapy.2017; 15(5): 435. CrossRef
What Is the Applicability of a Novel Surveillance Concept of Ventilator-Associated Events?
Miia Jansson, Tero Ala-Kokko, Lauri Ahvenjärvi, Jaana Karhu, Pasi Ohtonen, Hannu Syrjälä
Infection Control & Hospital Epidemiology.2017; 38(8): 983. CrossRef
Submillisievert chest dual energy computed tomography: a pilot study
Rodrigo Canellas, Jeanne B Ackman, Subba R Digumarthy, Melissa Price, Alexi Otrakji, Shaunagh McDermott, Amita Sharma, Mannudeep K Kalra
The British Journal of Radiology.2017; : 20170735. CrossRef
Evaluation of pulmonary nodules and infection on chest CT with radiation dose equivalent to chest radiography: Prospective intra-individual comparison study to standard dose CT
K. Martini, B.K. Barth, T.D.L. Nguyen-Kim, S. Baumueller, H. Alkadhi, T. Frauenfelder
European Journal of Radiology.2016; 85(2): 360. CrossRef
Reply to “Early Lung Computed Tomography Scan after Allogeneic Hematopoietic Stem Cell Transplantation”
Marie Alice Cornetto, Constance de Margerie-Mellon, Patricia Ribaud, Anne Bergeron
Biology of Blood and Marrow Transplantation.2016; 22(10): 1910. CrossRef

12,604 View
117 Download
31 Crossref

Analysis of Biologically Equivalent Dose of Stereotactic Body Radiotherapy for Primary and Metastatic Lung Tumors: Sungkwang Park, Sanghwa Urm, Heunglae Cho; Cancer Res Treat. 2014;46(4):403-410. Published online July 17, 2014; DOI: https://doi.org/10.4143/crt.2013.168

Abstract PDF PubReader ePub

Purpose
The purpose of this study was to determine the optimal biologically equivalent dose (BED) for stereotactic body radiotherapy (SBRT) by comparing local control rates in proportion to various total doses and fractionation schedules. Materials and Methods Thirty-four patients with early non-small-cell lung cancer and a single metastatic lung tumor were included in this study. Differences in local control rates were evaluated according to gender, primary tumor site, response, tumor size, and BED. For comparison of BEDs, the prescribed dose for SBRT was stratified according to three groups: high (BED > 146 Gy), medium to high (BED, 106 to 146 Gy), and low to medium (BED < 106 Gy). Results For all patients, the overall local control rate was 85.3% at two years after treatment. Five local recurrences were observed, and, notably, all of them were observed in the low to medium BED group. Significantly higher local control rates were observed for patients with a complete response than for those with a partial response or stable disease (p < 0.001). Twenty-six patients with a tumor size of < 3 cm showed no dose-response relationship in the low to medium, medium to high, and high BED groups, whereas eight patients with a tumor size of ≥ 3 cm showed a significant dose-response relationship. The observed 2-year local recurrence-free survival rates in patients with a tumor size of < 3 cm and in those with a tumor size of ≥ 3 cm were 96.2% and 50.0%, respectively, which were significantly different (p=0.007). Conclusion BED > 100 Gy is required in order to achieve a > 85% local control rate regardless of tumor size. The optimal dose for small tumors of < 3 cm appears to be within a range below 150 Gy BED. Escalation of BED to high levels (> 150 Gy) may be required for patients with a tumor size larger than 3 cm.

Citations

Citations to this article as recorded by

The optimal treatment for patients with stage I non-small cell lung cancer: minimally invasive lobectomy versus stereotactic ablative radiotherapy – a nationwide cohort study
Julianne Cynthia de Ruiter, Vincent van der Noort, Judi Nani Annet van Diessen, Egbert Frederik Smit, Ronald Alphons Maria Damhuis, Koen Johan Hartemink, M.I. Amir, H. van Berkum, H. Bertens, M. Bindels, E.M. Bongers, R.C. Boshuizen, K. de Brake-de Jong,
Lung Cancer.2024; 191: 107792. CrossRef
Radiation Oncologists’ Perspectives on Oligometastatic Prostate Cancer: A Survey from Korean Oligometastasis Working Group
Gyu Sang Yoo, Sunmin Park, Chai Hong Rim, Won Kyung Cho, Ah Ram Chang, Young Seok Kim, Yong Chan Ahn, Eui Kyu Chie
Current Oncology.2024; 31(6): 3239. CrossRef
Stereotactic ablative radiotherapy for locally advanced non-small cell lung cancer: A systematic review and meta-analysis
Gustavo A. Viani, Andre G. Gouveia, Alexander V. Louie, Fabio Arcidiacono, Charles B. Simone, Theodoros Tsakiridis, Ana Carolina Hamamura, Paola Anselmo, Fabio Y. Moraes
Radiotherapy and Oncology.2024; 201: 110439. CrossRef
Treatment outcomes of stereotactic body radiation therapy for pulmonary metastasis from sarcoma: a multicenter, retrospective study
Tae Hoon Lee, Hak Jae Kim, Jin Ho Kim, Mi-Sook Kim, Won Il Jang, Eunji Kim, Kyung Su Kim
Radiation Oncology.2023;[Epub] CrossRef
Dosimetric evaluation of SBRT treatment plans of non-central lung tumours: clinical experience
Ernest Osei, Johnson Darko, Steph Swanson, Katrina Fleming, Ronald Snelgrove, Anmol Bhangu, Darin Gopaul
Journal of Radiotherapy in Practice.2022; 21(2): 179. CrossRef
Use of Multi-Site Radiation Therapy for Systemic Disease Control
Roshal R. Patel, Vivek Verma, Hampartsoum B. Barsoumian, Matthew S. Ning, Stephen G. Chun, Chad Tang, Joe Y. Chang, Percy P. Lee, Saumil Gandhi, Peter Balter, Joe Dan Dunn, Dawei Chen, Nahum Puebla-Osorio, Maria Angelica Cortez, James W. Welsh
International Journal of Radiation Oncology*Biology*Physics.2021; 109(2): 352. CrossRef
Ablative Radiotherapy for Patients With Inoperable Pancreas Cancer—Ready for Prime Time?
David P. Horowitz, Karyn Goodman, Lisa A. Kachnic
JAMA Oncology.2021; 7(5): 687. CrossRef
Evidence-Based Planning Target Volume Margin Reduction for Modern Lung Stereotactic Ablative Radiation Therapy Using Deformable Registration
Katie Jasper, Baochang Liu, Robert Olson, Quinn Matthews
Advances in Radiation Oncology.2021; 6(6): 100750. CrossRef
Radiotherapy and Immunotherapy Combinations in the Treatment of Patients with Metastatic Disease: Current Status and Future Focus
William Tyler Turchan, Sean P. Pitroda, Ralph R. Weichselbaum
Clinical Cancer Research.2021; 27(19): 5188. CrossRef
Predicting 5-Year Progression and Survival Outcomes for Early Stage Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy: Development and Validation of Robust Prognostic Nomograms
Jingjing Kang, Matthew S. Ning, Han Feng, Hongqi Li, Houda Bahig, Eric D. Brooks, James W. Welsh, Rui Ye, Hongyu Miao, Joe Y. Chang
International Journal of Radiation Oncology*Biology*Physics.2020; 106(1): 90. CrossRef
Stereotactic Body Radiation Therapy for the Definitive Treatment of Early Stage Kidney Cancer: A Survival Comparison With Surgery, Tumor Ablation, and Observation
Stephen R. Grant, Xiudong Lei, Kenneth R. Hess, Grace L. Smith, Surena F. Matin, Christopher G. Wood, Quynh Nguyen, Steven J. Frank, Mitchell S. Anscher, Benjamin D. Smith, Jose A. Karam, Chad Tang
Advances in Radiation Oncology.2020; 5(3): 495. CrossRef
The Effect of Concurrent Stereotactic Body Radiation and Anti-PD-1 Therapy for Recurrent Metastatic Sarcoma
Cameron M. Callaghan, Steven N. Seyedin, Imran H. Mohiuddin, Kelli L. Hawkes, Michael S. Petronek, Carryn M. Anderson, John M. Buatti, Mohammed M. Milhem, Varun Monga, Bryan G. Allen
Radiation Research.2020; 194(2): 124. CrossRef
Traitements locaux : indication et résultats dans les stades précoces
L. Padovani, C. Massabeau, J. Khalifa, P. Habert, J.-Y. Gaubert
Revue des Maladies Respiratoires Actualités.2020; 12(2): 2S79. CrossRef
Maximum standardized uptake value at pre-treatment PET in estimating lung cancer progression after stereotactic body radiotherapy
Jisun Park, Yunseon Choi, Ki Jung Ahn, Sung Kwang Park, Heunglae Cho, Ji Young Lee
Radiation Oncology Journal.2019; 37(1): 30. CrossRef
Calculating the individualized fraction regime in stereotactic body radiotherapy for non-small cell lung cancer based on uncomplicated tumor control probability function
Jia-Yang Lu, Pei-Xian Lin, Bao-Tian Huang
Radiation Oncology.2019;[Epub] CrossRef
La radiothérapie stéréotaxique: indication et résultats dans les stades précoces
C. Massabeau, J. Khalifa
Revue des Maladies Respiratoires Actualités.2019; 11(3): 255. CrossRef
GTV volume estimation using different mode of computer tomography for lung tumors in stereotactic body radiation therapy
Ramaa Lingaiah, Md Abbas Ali, Ummay Kulsum, Muhtasim Aziz Muneem, Karthick Raj Mani, Sharif Ahmed, Md. Shakilur Rahman, M Salahuddin
Polish Journal of Medical Physics and Engineering.2019; 25(1): 29. CrossRef
Correlation of biologically effective dose and the tumor control in Stage I (<5 cm) non-small cell lung cancer with stereotactic ablative radiotherapy: a single institutional cohort study
Wan Jeon, Sung-Ja Ahn, Young-Chul Kim, In-Jae Oh, Chul-Kyu Park, Jae-Uk Jeong, Mee Sun Yoon, Ju-Young Song, Taek-Keun Nam, Woong-Ki Chung
Japanese Journal of Clinical Oncology.2018; 48(2): 144. CrossRef
Using max standardized uptake value from positron emission tomography to assess tumor responses after lung stereotactic body radiotherapy for different prescriptions
Meisong Ding, William Zollinger, Robert Ebeling, David Heard, Ryan Posey
Journal of Applied Clinical Medical Physics.2018; 19(6): 226. CrossRef
Oligometastatische Erkrankung des nichtkleinzelligen Lungenkarzinoms
Severin Schmid, Bernward Passlick, Martin Stuschke, Frank Griesinger
Der Onkologe.2018; 24(12): 992. CrossRef
A feasibility study of spatiotemporally integrated radiotherapy using the LQ model
M Kim, M H Phillips
Physics in Medicine & Biology.2018; 63(24): 245016. CrossRef
Dosimetric comparison of deep inspiration breath hold and free breathing technique in stereotactic body radiotherapy for localized lung tumor using Flattening Filter Free beam
Karthick Raj Mani, Md. Anisuzzaman Bhuiyan, Md. Mahbub Alam, Sharif Ahmed, Mostafa Aziz Sumon, Ashim Kumar Sengupta, Md. Shakilur Rahman, Md. S. M. Azharul Islam
Polish Journal of Medical Physics and Engineering.2018; 24(1): 15. CrossRef
Stereotactic Ablative Body Radiotherapy for the Treatment of Spinal Oligometastases
J.H. Chang, S. Gandhidasan, R. Finnigan, D. Whalley, R. Nair, A. Herschtal, T. Eade, A. Kneebone, J. Ruben, M. Foote, S. Siva
Clinical Oncology.2017; 29(7): e119. CrossRef
Comparative Analysis of Local Control Prediction Using Different Biophysical Models for Non-Small Cell Lung Cancer Patients Undergoing Stereotactic Body Radiotherapy
Bao-Tian Huang, Wu-Zhe Zhang, Li-Li Wu, Pei-Xian Lin, Jia-Yang Lu
BioMed Research International.2017; 2017: 1. CrossRef
The role of stereotactic ablative radiotherapy (SBRT) in the management of oligometastatic non small cell lung cancer
Eduardo Guerrero, Merina Ahmed
Lung Cancer.2016; 92: 22. CrossRef
Hypofractionated radiotherapy for medically inoperable stage I non‐small cell lung cancer
Wei Jiang, Jian‐Yang Wang, Jing‐Bo Wang, Jun Liang, Zhou‐Guang Hui, Xiao‐Zhen Wang, Zong‐Mei Zhou, Lu‐Hua Wang
Thoracic Cancer.2016; 7(3): 296. CrossRef
Lung SBRT through Radiobiology
Aime M. Gloi
International Journal of Medical Physics, Clinical Engineering and Radiation Oncology.2016; 05(01): 78. CrossRef
Radiation Therapy Alone in cT1-3N0 Non-small Cell Lung Cancer Patients Who Are Unfit for Surgical Resection or Stereotactic Radiation Therapy: Comparison of Risk-Adaptive Dose Schedules
Won Kyung Cho, Jae Myoung Noh, Yong Chan Ahn, Dongryul Oh, Hongryull Pyo
Cancer Research and Treatment.2016; 48(4): 1187. CrossRef
Planning Target Volume D95 and Mean Dose Should Be Considered for Optimal Local Control for Stereotactic Ablative Radiation Therapy
Lina Zhao, Shouhao Zhou, Peter Balter, Chan Shen, Daniel R. Gomez, James D. Welsh, Steve H. Lin, Joe Y. Chang
International Journal of Radiation Oncology*Biology*Physics.2016; 95(4): 1226. CrossRef
Clinical characteristics and dose-volume histogram parameters associated with the development of pleural effusions in non-small cell lung cancer patients treated with chemoradiation therapy
Matthew P. Deek, Sairaman Nagarajan, Sinae Kim, Inaya Ahmed, Shiby Paul, Eli D. Scher, Matthew Listo, Andrew Chen, Joseph Aisner, Sabiha Hussain, Bruce G. Haffty, Salma K. Jabbour
Acta Oncologica.2016; 55(8): 1029. CrossRef
Impact of Fractionation and Dose in a Multivariate Model for Radiation-Induced Chest Wall Pain
Shaun U. Din, Eric L. Williams, Andrew Jackson, Kenneth E. Rosenzweig, Abraham J. Wu, Amanda Foster, Ellen D. Yorke, Andreas Rimner
International Journal of Radiation Oncology*Biology*Physics.2015; 93(2): 418. CrossRef
A feasibility study: Selection of a personalized radiotherapy fractionation schedule using spatiotemporal optimization
Minsun Kim, Robert D. Stewart, Mark H. Phillips
Medical Physics.2015; 42(11): 6671. CrossRef
Radiobiological modeling analysis of the optimal fraction scheme in patients with peripheral non-small cell lung cancer undergoing stereotactic body radiotherapy
Bao-Tian Huang, Jia-Yang Lu, Pei-Xian Lin, Jian-Zhou Chen, De-Rui Li, Chuang-Zhen Chen
Scientific Reports.2015;[Epub] CrossRef
A Theoretical Study: Selection of a Personalized Radiotherapy Fractionation Schedule Using Spatiotemporal Optimization
Minsun Kim, Robert Stewart, Mark H Phillips
SSRN Electronic Journal.2015;[Epub] CrossRef

12,801 View
77 Download
35 Web of Science
34 Crossref

Case Reports

A New Approach to the Treatment of Metastatic Paraganglioma: Sorafenib: Meral Gunaldi, Ismail Oguz Kara, Berna Bozkurt Duman, Cigdem Usul Afsar, Melek Ergin, Arbil Avci; Cancer Res Treat. 2014;46(4):411-414. Published online July 18, 2014; DOI: https://doi.org/10.4143/crt.2013.093

Abstract PDF PubReader ePub

Paragangliomas are relatively rare chromaffin cell tumors which may be cured through resection. Patients with paragangliomas may develop metastatic diseases. There is no consensus regarding refractory chemotherapy for treatment of metastatic disease. In this report, we presented a case of a 43-year-old woman who was admitted to the hospital with a history of episodic headaches, diaphoresis, and weakness. Elevated plasma catecholamine levels and a right paraaortic mass were observed on computed tomography. The mass was excised, and a diagnosis of paraganglioma was confirmed. After 20 months of follow up, local recurrence and metastases were detected in the thorax, abdomen, and skeletal system. Plasma and urinary catecholamine levels were high. Chemotherapy was administered, and no improvement was observed. Therefore, following this palliative conventional chemotherapy, Sorafenib was administered for three months, and, finally, Positron Emission Tomography showed that the patient’s lesions had completely regressed.

Citations

Citations to this article as recorded by

The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma
Song Peng, Jun Zhang, Xintao Tan, Yiqiang Huang, Jing Xu, Natalie Silk, Dianzheng Zhang, Qiuli Liu, Jun Jiang
Frontiers in Endocrinology.2020;[Epub] CrossRef
Primary Pulmonary Paraganglioma
Xin Huang, Qi-Lian Liang, Liang Jiang, Qiu-Long Liu, Wen-Ting Ou, Da-Heng Li, Hui-Jie Zhang, Gao-Le Yuan
Medicine.2015; 94(31): e1271. CrossRef

11,854 View
97 Download
3 Web of Science
2 Crossref

Pleural Metastasis as Initial Presentation of Occult Gastric Cardia Cancer: A Possible Role of PET-CT in Diagnosis: So Young Yoon, Jeong Hwan Kim, Wan Seop Kim, Hyun Woo Chung, Mark Hong Lee, Sung Yong Kim, Yo Han Cho; Cancer Res Treat. 2014;46(4):415-418. Published online July 18, 2014; DOI: https://doi.org/10.4143/crt.2013.068

Abstract PDF PubReader ePub: We report on a case of malignant pleural effusion as initial metastatic presentation of occult gastric cardia cancer in a young woman. To the best of our knowledge, this is the first report of gastric adenocarcinoma metastasized to pleura as an initial presentation. Location of cardia and signet ring cell histology may contribute to the manifestation. Utilization of PET/CT was helpful for proper diagnosis. For patients with such distinct clinical presentations, it would be appropriate to consider gastric cancer as one of the possible primary sites.

11,128 View
58 Download

Bladder and Liver Involvement of Visceral Larva Migrans May Mimic Malignancy: Eun Joo Kang, Yoon Ji Choi, Jung Sun Kim, Byung Hyun Lee, Ka-Won Kang, Hong Jun Kim, Eun Sang Yu, Yeul Hong Kim; Cancer Res Treat. 2014;46(4):419-424. Published online July 18, 2014; DOI: https://doi.org/10.4143/crt.2013.104

Abstract PDF PubReader ePub

Visceral larva migrans (VLM) syndrome is a clinical manifestation of systemic organ involvement by Toxocara species. VLM with involvement of the bladder and liver is a rare finding. A 62-year-old woman presented with diffuse bladder wall thickening and multiple liver masses with peripheral eosinophilia and urinary symptoms. We considered malignancy or eosinophilic cystitis through clinical manifestations and imaging findings. However, no suspicious malignant lesions were observed on cystoscopy and liver mass biopsy revealed the presence of eosinophilic necrotizing granuloma without malignant cells. Anti-Toxocara antibodies were detected by western blotting and the patient was diagnosed with VLM syndrome. After taking prednisolone, urinary symptoms disappeared. On abdominal CT scan taken after three months, the size of multiple liver masses and bladder wall thickening had decreased. VLM syndrome should be suspected in patients with an atypical imaging pattern and peripheral eosinophilia.

Citations

Citations to this article as recorded by

Pulmonary and Liver Toxocariasis Mimicking Metastatic Tumors in a Patient with Colon Cancer
Miju Cheon, Jang Yoo
Diagnostics.2023; 14(1): 58. CrossRef
Eosinophilic Granuloma of the Liver Mimicking Metastatic Liver Tumor
Yotaro Uchida, Keiji Yokoyama, Tomotaka Higashi, Takanori Kitaguchi, Hiromi Fukuda, Ryo Yamauchi, Naoaki Tsuchiya, Atsushi Fukunaga, Kaoru Umeda, Kazuhide Takata, Takashi Tanaka, Yasuaki Takeyama, Satoshi Shakado, Shotaro Sakisaka, Hiroyuki Hayashi, Yoshi
Internal Medicine.2022; 61(10): 1511. CrossRef
Toxocariasis-associated urinary system diseases: a systematic review of reported cases
Ali Ardekani, Amirhossein Roshanshad, Seyed Ali Hosseini, Jean-François Magnaval, Ali Abdollahi, Ali Rostami
Transactions of The Royal Society of Tropical Medicine and Hygiene.2022; 116(7): 668. CrossRef
Toxocariasis Suspected of Having Infiltrated Directly from the Liver to the Lung through the Diaphragm
Masaki Kakimoto, Masayuki Murata, Fujiko Mitsumoto-Kaseida, Eiichi Ogawa, Yuji Matsumoto, Akira Kusaga, Kazuhiro Toyoda, Takeo Hayashi, Kazuya Ura, Keishi Kanno, Norihiro Furusyo, Susumu Tazuma
Internal Medicine.2019; 58(18): 2737. CrossRef
Klasyczne i nowoczesne metody diagnozowania toksokarozy u dzieci
Anna Kroteń, Artur Sulik, Elżbieta Ołdak
Pediatria Polska.2015; 90(4): 319. CrossRef

14,972 View
84 Download
5 Web of Science
5 Crossref

Correspondences

Commentary on “A Nationwide Survey of Knowledge of and Compliance with Cancer Pain Management Guidelines by Korean Physicians”: Kieran Walsh; Cancer Res Treat. 2014;46(4):425-425. Published online July 31, 2014; DOI: https://doi.org/10.4143/crt.2014.123C

PDF PubReader ePub

7,401 View
42 Download

Reply to Commentary on “A Nationwide Survey of Knowledge of and Compliance with Cancer Pain Management Guidelines by Korean Physicians”: Do Yeun Kim, Si-Young Kim; Cancer Res Treat. 2014;46(4):426-426. Published online July 31, 2014; DOI: https://doi.org/10.4143/crt.2014.123R

PDF PubReader ePub

8,493 View
61 Download

First
Prev
Page of 1
Next
Last

Previous issues